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Introduction
Inflammatory bowel diseases (IBDs), which include Crohn's disease and ulcerative colitis, are characterized by chronic relapsing idiopathic inflammation of the gastrointestinal tract that is associated with long-term and sometimes irreversible impairment of gastrointestinal structure and function (Podolsky, 2002) . Patients with IBDs suffer from inflammation-induced 'leak flux' diarrhea caused by a passive loss of ions and water from the circulation into the intestinal lumen as a result of an impaired intestinal barrier (Hering et al., 2012) . The chronic intestinal inflammation is induced by multiple exogenous and endogenous signals and mediated by various immune cells (de Souza and Fiocchi, 2016) . The exogenous substances include dietary antigens, gut microbiota-derived microbe-associated molecular patterns, pathogens, and xenobiotics, all of which undergo epithelial translocation and thus activate the intestinal immune responses in patients with IBDs (de Souza and Fiocchi, 2016) . Therefore, one therapeutic strategy for IBDs is to suppress inflammation, and anti-inflammatory agents including steroids, thiopurines, methotrexate, and monoclonal antibodies to tumor necrosis factor α (TNFα) have been incorporated into treatment regimens (de Souza and Fiocchi, 2016) . However, many patients have to stop these therapies because of adverse drug effects or lack of therapeutic responses (Bravata et al., 2015) .
Despite the role of epithelial translocation of exogenous substances in the activation of intestinal immune responses in IBDs (de Souza and Fiocchi, 2016) , therapeutic interventions targeted at the epithelial translocation have never been fully developed.
Chronic inflammation in IBDs compromises the intestinal epithelial monolayer.
Concentrations of the pro-inflammatory cytokine TNFα are increased in Crohn's disease
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JPET/2017/242214 5 and ulcerative colitis (Podolsky, 2002) . To maintain the barrier function of the intestinal epithelium, its intercellular spaces are sealed by tight junctions (TJs), which prevent the free movement of solutes (ions, water, and noxious antigens derived from foods or microorganisms) across epithelial sheets (Powell, 1981) . The intercellular TJ seal is impaired in colonic samples from IBD patients (Zeissig et al., 2007) , and TNFα plays a pivotal role in the disruption of TJ seals, perhaps through altered regulation of TJ components (Schmitz et al., 1999; Burgel et al., 2002; Amasheh et al., 2009; Mankertz et al., 2009 ).
Freeze-fracture analysis showed that TJ seals consist of a set of continuous, anastomosing intramembranous strands (Staehelin, 1974) . TJs comprise transmembrane proteins (junctional adhesion molecules, occludin, claudins [CLDNs] , and tricellulin) and intracellular scaffolding proteins (zonula occludens) (Van Itallie and Anderson, 2014) . CLDNs are key components of the TJ seal. CLDNs are a family containing 27 members which show tissue-specific expression profiles. CLDN1, 3, 4, 5, 7, and 8 are frequently observed in tight epithelia, whereas CLDN2 is primarily expressed in leaky epithelia (Luettig et al., 2015) . Colon biopsies from patients with IBDs showed decreased expression of CLDN3, 5, and 8 and occludin and increased CLDN2 expression (Zeissig et al., 2007) .
CLDN2 is a 24.5-kDa tetra-transmembrane protein with 2 extracellular loop domains (Furuse et al., 1998b) . Transfection with a plasmid encoding CLDN2 decreases the integrity of TJs, due to the formation of discontinuous TJ strands (Furuse et al., 2001) .
Treatment with TNFα upregulates the expression of CLDN2 in part via phosphatidylinositol-3-kinase (PI3K) signaling (Prasad et al., 2005; Heller et al., 2008; Mankertz et al., 2009; Amasheh et al., 2010; Suzuki et al., 2011) , whereas anti-TNFα This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on September 19, 2017 as DOI: 10.1124 at ASPET Journals on November 19, 2017 jpet.aspetjournals.org
JPET/2017/242214 6 monoclonal antibody (mAb) prevents the TNFα-induced loss of TJ integrity and the associated downstream effects on PI3K and CLDN2 (Fischer et al., 2013) . Furthermore, the administration of an anti-TNFα antibody restores intestinal barrier function in patients with Crohn's disease (Suenaert et al., 2002; Noth et al., 2012) . These findings indicate that inhibition of CLDN2 may restore the diminished TJ integrity in IBDs.
However, whether CLDN2 is a feasible target for IBD therapy has been unknown because a CLDN2-specific inhibitor had not been developed.
In this study, we used a DNA immunization method to generate a mAb that specifically recognizes the first extracellular loop of CLDN2, and we investigated the effects of this mAb on TNFα-induced loss of TJ integrity in cell culture models. 
Materials and methods

Reagents
Anti-histidine tag mAb, fluorescein isothiocyanate (FITC)-conjugated antibody, rat IgG, anti-β-actin antibody, and TNFα were obtained from ThermoFisher Scientific and anti-CLDN3 and -4 mAb (5A5) were prepared as described previously Kuwada et al., 2015) . The anti-TNFα monoclonal antibodies infliximab (Remicade; Mitsubishi Tanabe Pharma Corporation (Osaka, Japan)) and adalimumab (Humira; Eisai (Tokyo, Japan)) were purchased from reagent distributors.
Cell cultures
Because they are CLDN-negative, HT1080 cells (a human fibrosarcoma cell line) are used to characterize CLDN binders (Neesse et al., 2013; Fukasawa et al., 2015; Mosley et al., 2015; Nakajima et al., 2015) . HT1080 cells mock-transfected or stably transfected with human CLDN1-CLDN7, or CLDN9 (mock/HT1080, hCLDN1/HT1080 to hCLDN7/HT1080, and hCLDN9/HT1080 cells, respectively) were previously established (Li et al., 2014) . hCLDN/HT1080 cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at 37 °C under 5% CO 2 .
L cells that stably expressed mouse CLDN1 or CLDN2 (mCLDN1/L and mCLDN2/L cells, respectively) were kindly provided by Dr. S. Tsukita (Kyoto University, Kyoto, Japan). mCLDN/L cells were cultured in modified Eagle's medium containing 10% fetal bovine serum at 37 °C under 5% CO 2 .
This article has not been copyedited and formatted. The final version may differ from this version. were purchased from Shimizu Laboratory Supplies (Kyoto, Japan) and SLC, Inc., (Shizuoka, Japan), respectively. All animals were maintained under controlled conditions of a 12:12-h light:dark cycle at 23 ± 1.5 °C. The rodents had unrestricted access to food and water. All of the experimental protocols conformed to the ethics guidelines of the Graduate School of Pharmaceutical Sciences, Osaka University.
Preparation of a CLDN-binding peptide
We previously created m19, a peptide that binds to CLDNs 1, 2, 4, and 5, by using the CLDN3/4-binding polypeptide C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE) as a template (Takahashi et al., 2012) . We then prepared m19 tagged with a histidine tag at the N-terminus. Briefly, pET16b plasmid encoding m19 was transformed into Escherichia coli strain BL21 (DE3), and the production of the 
Generation of anti-CLDN2 mAb
Female Wistar rats (age, 6 weeks) were immunized with a eukaryotic expression vector encoding human CLDN2 every 2 weeks for 2 months according to proprietary technology (Genovac, Freiburg, Germany). Lymphocytes were removed 7 days after the last immunization and fused with P3UI cells in the presence of polyethylene glycol 1000, thus generating hybridoma cells. Hybridoma cells producing anti-CLDN2 mAbs were initially screened for the ability of their conditioned medium to bind to hCLDN2/HT1080 cells but not to mock/HT1080 cells, resulting in the isolation of a hybridoma that produced mAb against hCLDN2 (clone 1A2). The immunoglobulin class and subclass of anti-CLDN2 1A2 were determined by using a rat immunoglobulin isotyping enzyme-linked immunosorbent assay kit (BD Biosciences).
Purification of mAb
According to standard procedures, female BALB/c Slc-nu/nu mice (age, 8 weeks; SLC, Inc., Shizuoka, Japan) were each intraperitoneally injected with the adjuvant pristane (Sigma-Aldrich) and 1 × 10 7 mAb-producing hybridoma cells. Ascites was collected, and the mAb was purified by using a protein G column (GE Healthcare).
Eluted antibodies were dialyzed in PBS. The concentration of the purified antibody was determined by measuring the absorbance at 280 nm. 
Chimeric CLDN2/HT1080 cells
In CLDN2 cDNA, the sequences encoding the first extracellular loop domain (corresponding to amino acids 28 through 78) of hCLDN2, the second extracellular loop domain (corresponding to amino acids 144 through 162) of hCLDN2, or the first and second loop domains of hCLDN2 were genetically replaced by those of hCLDN4, resulting in hCLDN2/EL1-hCLDN4, hCLDN2/EL2-hCLDN4, or hCLDN2/EL1 and EL2-hCLDN4 cDNA. The resultant cDNAs were cloned into pcDNA3.1(-) (Invitrogen).
The chimeric hCLDN2 expression vectors were then transfected into HT1080 cells by 
Assay of TJ integrity
Caco were then normalized to the surface area of the well.
Assay of TJ integrity in TNFα-treated Caco-2 monolayers
Caco-2 cells were seeded into 24-well Transwell inserts (6.0 × 10 4 cells/0.33 cm measured 24 h before and 24 h after treatment. Alternatively, the Caco-2 cells were pre-treated with TNFα (10 ng/mL) for 24 h and then rat IgG (10 µg/mL) or anti-CLDN2 mAb 1A2 (10 µg/mL) was added; the cells were cultured, and TEER values were measured.
To investigate the effects of anti-TNFα mAb and anti-CLDN2 mAb, the cells were pre-treated with TNFα (10 ng/mL) for 24 h, after which anti-TNFα mAb (infliximab or adalimumab), anti-CLDN2 mAb 1A2, or a mixture of anti-TNFα mAb and anti-CLDN2 mAb 1A2 was added to the medium (10 µg/mL per reagent). TEER values were measured after treatment.
Immunoblot analysis
MDCK I or Caco-2 cells were collected by using a cell scraper and lysed in buffer 
Statistical analysis
Data were analyzed by using Tukey's test. The statistical significance for all comparisons was set at P < 0.05.
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Results
Generation of anti-CLDN2 mAbs
CLDN2 forms homodimers with adjacent CLDN2 or heterodimers with CLDN3, but does not interact with CLDN1 (Furuse et al., 1999) , and single-molecule force spectroscopy revealed that these trans-interactions are mediated through the first extracellular loop domain of CLDN2 (Lim et al., 2008) . We therefore hypothesized that a molecule that binds to an extracellular domain of CLDN2 would prevent the formation of leaky barriers caused by CLDN2, thus attenuating the CLDN2-mediated impairment of the TJ seal in IBDs. To address this hypothesis, we first tried to generate mAbs that recognized one or both of the extracellular loop domains of CLDN2. We previously generated anti-CLDN1 and anti-CLDN4 mAbs by immunizing mice and rats with plasmid DNA encoding human CLDN1 (hCLDN1) and hCLDN4 cDNA, respectively (Li et al., 2014; Fukasawa et al., 2015) . Therefore, we immunized rats with plasmid DNA encoding hCLDN2 and selected hybridoma cells that produced anti-CLDN2 mAbs, which bound to hCLDN2/HT1080 cells but not to mock/HT1080 cells; these efforts resulted in the generation of a hybridoma clone that produced anti-CLDN2 mAb (1A2). The immunoglobulin subtype of 1A2 is IgG2b. 1A2 bound to hCLDN2/HT1080 cells but not to HT1080 cells that stably expressed hCLDN1, 3, 4, 6, 7, or 9 (Fig. 1A) ; 1A2 also bound to mouse CLDN2 (mCLDN2)/L cells (Fig. 1A) .
These findings indicate that mAb 1A2 is a specific binder of CLDN2.
To determine the extracellular domain(s) to which 1A2 binds, we replaced either or both of the extracellular loop domains of CLDN2 with those of CLDN4. The broadly reactive CLDN binder m19, which binds to CLDNs 1-5, bound to all of these chimeric (Fig. 1B) . In contrast, mAb 1A2 only bound to fractions containing the first extracellular domain of CLDN2 (Fig. 1B) . Therefore, mAb 1A2 specifically recognizes the first extracellular loop domain of hCLDN2.
Effects of anti-CLDN2 mAb on TJ integrity
Monolayers of Caco-2 cells are widely used as an in vitro model of the human intestinal epithelial barrier (Meunier et al., 1995; Wang et al., 2005) . Therefore, to assess whether a CLDN2 binder might attenuate the CLDN2-induced impairment of epithelial TJ integrity, we investigated the effects of anti-CLDN2 mAb on TJ integrity in Caco-2 cell monolayers. mAb 1A2 increased TEER values to 133%, and the removal of 1A2 from the medium attenuated changes in TEER ( Fig. 2A) . Furthermore, 1A2
dose-dependently increased TEER (Fig. 2B ).
To confirm the CLDN2 specificity of the 1A2-induced increase in TJ integrity, we investigated the effects of mAbs specific for CLDN1 (7A5), CLDN4 (5D12), and CLDN3/4 (5A5) on TJ integrity (Li et al., 2014; Fukasawa et al., 2015) . Treatment of Caco-2 monolayers with mAb specific for CLDN1 (7A5) or CLDN4 (5D12) (10 µg/mL) did not significantly change TEER from that of the vehicle-only control, and treatment for 24 h with the CLDN3/4 dual-specific mAb (5A5) decreased TEER to 78%
of that of the vehicle control (Fig. 2C ). In addition, we transfected MDCKI cells, which do not express CLDN2, to stably express CLDN2 and examined the effect of mAb 1A2 on TJ integrity. Treatment with mAb 1A2 increased TEER in MDCKI/CLDN2 cells but not MDCKI/vector cells (Suppl. Fig. 1 ). Similarly, mAb 1A2 induced a greater increase in the TEER of Caco-2 cells exogenously expressing CLDN2 compared with Caco-2/vector cells (Suppl. Fig. 2) . Therefore, the ability of 1A2 to promote TJ integrity 
Effects of anti-CLDN2 mAb on TNFα-induced TJ dysfunction
To investigate the effects of the anti-CLDN2 mAb 1A2 on the disruption of TJ integrity in the context of inflammation, we used a Caco-2 model of TNFα-induced TJ dysfunction (Ma et al., 2005; Graham et al., 2006) . Treatment of cells with TNFα (10 ng/mL) for 24 h decreased TEER to 70% of that at 0 h, accompanied by an increase in cellular CLDN2 protein content (Fig. 3A , Suppl. Fig. 3 ). In contrast, co-treatment with TNFα and anti-CLDN2 mAb (1A2) attenuated the reduction in TEER (Fig. 3A) . To clarify the effects of anti-CLDN2 mAb in the TNFα-induced dysfunction model, Caco-2 cells were exposed to TNFα for 24 h and then treated with anti-CLDN2 mAb for 48 h.
In cells exposed to TNFα for 24 h followed by 48-h treatment with vehicle only or rat
IgG, TEER decreased to 37% or 39% of that before TNFα treatment, respectively (Fig.   3B ). In contrast, anti-CLDN2 mAb treatment attenuated the TNFα-induced reduction in
TEER to approximately 64% of that before TNFα treatment.
To investigate whether the effects of mAbs against CLDN2 and TNFα might be additive, we pretreated Caco-2 cells with TNFα (10 ng/mL) for 24 h and then exposed the cells for 48 h to anti-CLDN2 mAb (1A2), anti-TNFα mAb (infliximab or adalimumab), or both anti-CLDN2 and anti-TNFα mAbs concurrently. Pretreatment with TNFα reduced TEER to approximately 48% of that of untreated cells (Fig. 3C ).
However, exposure to anti-CLDN2 mAb, infliximab, or adalimumab (10 µg/mL each)
for 48 h recovered TEER to 75%, 60%, or 62% of the levels of cells before TNFα treatment, respectively, and co-treatment with anti-CLDN2 mAb and either infliximab or adalimumab increased TEER to 93% and 85%, respectively, of that of cells before 
Discussion
The activation of mucosal immune responses and impairment of the intestinal barrier are key characteristics of IBDs (Podolsky, 2002) . Various attenuators of these immune responses, including steroids, thiopurines, methotrexate, and anti-TNFα mAbs, are used clinically to treat patients with IBDs (de Souza and Fiocchi, 2016) . However, therapeutic agents targeting the intestinal barrier function have not been fully developed previously, in part due to a delay in understanding the mechanism underlying the impairment of the intestinal barrier function. In the present study, we hypothesized that CLDN2, a characteristic component of leaky TJ seals, might be an effective target through which to increase TJ integrity for IBD therapy. We consequently generated a mAb that recognized the first extracellular loop domain of CLDN2; the mAb restored the TJ seal function in cultures of TNFα-treated cells.
Infliximab and adalimumab, commercially available anti-TNFα mAbs, prevent the intestinal barrier dysfunction due to TNFα treatment, which increases the expression of CLDN2 (Fischer et al., 2013) . Butyrate, a short-chain fatty acid, prevents chemical-induced colitis, accompanied by downregulation of CLDN2 (Vieira et al., 2012) . Berberine, a plant alkaloid, is a traditional Eastern medicine for the treatment of diarrhea and gastroenteritis (Rosenthal et al., 2010) ; like butyrate, berberine downregulates CLDN2, the effect that is associated with berberine's antidiarrheal properties. These findings strongly support our data regarding the use of an anti-CLDN2 mAb to treat the TNFα-induced dysfunction of TJ seals in the intestinal epithelium of patients with IBDs. However, butyrate downregulated 161 genes, including CLDN2 (Vieira et al., 2012) , and berberine inhibited the PI3K-Akt signaling pathway, which regulates CLDN2 expression (Rosenthal et al., 2010) . Therefore, butyrate and berberine are not specific inhibitors of CLDN2, and as such, their use for IBD therapy might cause unexpected adverse effects. In addition, CLDN2 was detectable in the colons of IBD patients but not in the colons of healthy people (Heller et al., 2005; Zeissig et al., 2007; Oshima et al., 2008) . Accordingly, one key therapeutic benefit of an anti-CLDN2 mAb is its apparent specificity.
CLDN2 forms paracellular channels for cations and water (Amasheh et al., 2002 . Incorporation of CLDN2 into TJ strands does not change their number but rather makes them discontinuous, resulting in the formation of TJ seals that are leaky to solutes (Furuse et al., 2001) . CLDN2 forms homodimers with adjacent CLDN2 or heterodimers with CLDN3, but CLDN2 does not interact with CLDN1 (Furuse et al., 1999) . Trans-interaction in CLDN2 homodimers is mediated by the first extracellular domains of each unit through electrostatic interactions with D65 and weaker interactions with negatively charged π electrons of the Y67 aromatic residue (Lim et al., 2008) . Our anti-CLDN2 mAb 1A2 recognized the first extracellular domain of CLDN2.
Given these findings, the binding of an anti-CLDN2 mAb to CLDN2 might prevent cisand trans-interactions of CLDN2, thus attenuating the formation of leaky TJ seals.
CLDN2 is expressed in normal tissues, including liver, kidney, and small intestine (specifically the crypt-villus axis in humans), but not in the human colon (Furuse et al., 1998a; Enck et al., 2001; Kiuchi-Saishin et al., 2002; Lameris et al., 2013) .
CLDN2-deficient mice are normal in appearance, activity, growth, and behavior and lack functional and histologic abnormalities of liver, kidney, and small intestine (Muto et al., 2010; Tamura et al., 2011) . Therefore, CLDN2 might be a safe target for IBD therapy.
